ZUG, Switzerland — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that two articles have been published back-to-back in the same...

AUSTIN, Texas — IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T), a rare, progressive, inherited neurodegenerative disorder. This submission represents the first regulatory application submitted to the U.S. Food...

HANOVER, New Hampshire – Among people with cystic fibrosis (CF) who develop kidney failure, getting a kidney transplant may extend survival by nearly two decades compared with other types of care, a new study found. The transplanted kidneys also showed favorable long-term outcomes in people with CF, remaining functional for about...